SPY755.80−0.53%QQQ684.25−0.89%BTC/USD73,891.96+0.26%DIA524.02−0.08%GLD365.30+0.04%TLT80.87−0.06%

AstraZeneca PLC

AZNNYSE

$185.48

-1.28-0.69%

Last update: Nov 11, 4:00 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

M&A: Omniose was acquired by AstraZeneca (AZN) on Tuesday, November 10, 2026

AstraZeneca (AZN) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for AstraZeneca (AZN) stock.

Analyst Consensus — 10 Analysts

7Buy

3Hold

# Analysts10

Latest Upgrades and Downgrades for AstraZeneca Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	CICC	Yuan Guo	Initiate	Outperform	$198
—	Jefferies	Michael Leuchten	Assumes	Hold→Buy	—
—	UBS	Matthew Weston	Upgrade	Neutral→Buy	—
—	UBS	Matthew Weston	Upgrade	Sell→Neutral	—
—	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
—	TD Cowen	Steve Scala	PT Raise	Buy	$90→$95
—	Argus Research	Jasper Hellweg	PT Raise	Buy	$80→$85
—	Goldman Sachs	Rajan Sharma	Initiate	Buy	$97
—	BMO Capital	Etzer Darout	PT Raise	Outperform	$80→$82
—	Deutsche Bank	Emmanuel Papada	Upgrade	Sell→Hold	—
—	BMO Capital	Etzer Darout	PT Cut	Outperform	$82→$80
—	Deutsche Bank	Emmanuel Papadakis	Downgrade	Buy→Hold	—
—	Morgan Stanley	Mark Purcell	Initiate	Overweight	$85
—	Jefferies	Peter Welford	Downgrade	Buy→Hold	—

AstraZeneca PLC

AstraZeneca (AZN) Stock Price Target 2026

Latest Upgrades and Downgrades for AstraZeneca Stock

AstraZeneca (AZN) Stock Price Target 2026

Latest Upgrades and Downgrades for AstraZeneca Stock

Analyst Ratings News

AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

This $3 Biotech Could Be Worth $11.45, Analyst Says

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PRO
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

People Also Watch

People Also Watch

Analyst Ratings News

AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

This $3 Biotech Could Be Worth $11.45, Analyst Says

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PRO
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

AstraZeneca PLC

AstraZeneca (AZN) Stock Price Target 2026

Latest Upgrades and Downgrades for AstraZeneca Stock

AstraZeneca (AZN) Stock Price Target 2026

Latest Upgrades and Downgrades for AstraZeneca Stock

Analyst Ratings News

AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

This $3 Biotech Could Be Worth $11.45, Analyst Says

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PROCNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

People Also Watch

People Also Watch

Analyst Ratings News

AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

This $3 Biotech Could Be Worth $11.45, Analyst Says

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PROCNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

PRO
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury

PRO
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury